Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTALK: Brigatinib and Local Ablative Therapy in Advanced ALK+ NSCLC
NCT06620835Phase 2Recruiting
- Sponsor
- Groupe Français de Pneumo-Cancérologie
- Start
- Jun 2025
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Groupe Français de Pneumo-Cancérologie. Primary endpoint: Progression-Free Survival (Centrally Assessed) up to 3 years. Started Jun 2025; status: recruiting.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06620835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620835.